Controversies in ILD This deep dive into controversies in interstitial lung disease explored complex topics including IPAF, methotrexate, systemic autoimmune rheumatic disease vs. connective tissue disease distinctions, and the evolving role of anti-fibrotic therapy. Panelists: https://t.co/ekP1Gg73yj

GLP-1 drugs cost-effective for knee osteoarthritis and obesity A new study led by investigators at Mass General Brigham finds that adding novel weight loss GLP-1 drugs semaglutide and tirzepatide to usual care represents a cost-effective treatment strategy for people with knee https://t.co/pqWDEUgYmI

🆕 Collaboration with @RheumNow 🔵 3-Part Series on #InterstitialLungDisease Part2️⃣: Diagnosis & Subtypes of #ILD 🫁 👩🏻‍⚕️ What to look for on Physical Exam 🧪 Serologic Testing & Diagnostic Workup 🫁 Differentiating ILD Subtypes on Imaging #RheumX #Pulmonology #MedTwitter #MedX https://t.co/X8cJVx2PCV

SARD-ILD: Significant diagnostic and treatment delays Should we be screening all our patients with systemic autoimmune rheumatic disease (SARD) for interstitial lung disease? https://t.co/WyccifEHtY https://t.co/S6X5AhZCjz

Infections cause high morbidity & mortality in our immunocompromised rheum patients: vaccinations are essential to keep them healthy. Best time to administer vaccines? 1. Before immunosuppression 2 during periods of dz control 3. >1 vaccines need pt input @LCalabreseDO #CCRW25 https://t.co/oBgXlIk1TY

KDIGO is excited to share the publication of the 2025 Clinical Practice Guideline for the Management of IgA Nephropathy (#IgAN) and IgA Vasculitis (#IgAV), along with the Executive Summary in @Kidney_Int. Read the Guideline in KI: https://t.co/Ygwhu3rizm Download the Executive https://t.co/jio8N1C7KP

August 29, 2025, FDA has terminated the Arthritis Advisory Committee, citing infrequent meetings & that the effort and expense of maintaining the committee “is no longer justified.” The committee last met on 5/6/21 to review avacopan - that was subsequently approved. REALLY? https://t.co/w3Z6TszeWZ

Join us Sept 23 @ 7PM ET for the next Rheum to Breathe Journal Club! We’ll dive into two pivotal ILD studies: 📄 FIBRONEER (Nerandomilast in PPF) – NEJM 2025 📄 RECITAL (Rituximab vs Cyclophosphamide in CTD-ILD) – Lancet Panelists: Dr. Toby Maher, Dr. Shervin Assassi Moderator: https://t.co/l8EkX2hkLs

ILD and Mortality in Systemic Autoimmune Rheumatic Diseases Dr. Bryant England, Lincoln, NE, discusses interstitial lung disease and mortality in systemic autoimmune rheumatic diseases (SARDs), as part of RheumNow's Rheum to Breathe: ILD campaign, presented throughout the month https://t.co/wtg9Te6oth

SARD-ILD and serious infection risk: The elephant in the room Interstitial lung disease (ILD) remains one of the largest unmet clinical needs across many systemic autoimmune rheumatic diseases (SARD). ILD is highly prevalent across systemic sclerosis, mixed connective tissue https://t.co/oxIteGfUTd

QD Clinic: Application of the ACR CHEST Guidelines to Two Cases Dr. Sindhu Johnson, Toronto, discusses two cases that where the application of the ACR CHEST guidelines for the screening, monitoring and treatment of SSc-ILD and Rapidly Progressive ILD are applied, as part of https://t.co/ntW2WIvJ8c